Gemcitabine Therapy in Non-Small Cell Lung Cancer: A Review

  • Thierry Le Chevalier
Conference paper
Part of the ESO Monographs book series (ESO MONOGRAPHS)


The treatment of advanced non-small cell lung cancer (NSCLC) has not made very significant progress with regard to response rates and survival in the last decade. Few single agents have, in large studies, achieved response rates of more than 15%, while combination treatment gives response rates of 25% to 35% [1–4]. Several randomised studies comparing chemotherapy with best supportive care have yielded predominantly slightly favourable results for chemotherapy [5]. Two recent meta-analyses of the literature indicated a significant but modest survival advantage for the use of platinum-containing combination treatment compared with best supportive care [6,7].


Clin Oncol Stage IIIB Good Supportive Care Gemcitabine Therapy Current Therapeutic Modality 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Lenzi R, Fossella FV, Lee JS: Systemic treatment of non-small cell lung cancer. Compre Ther 1992 (18): 27–30Google Scholar
  2. 2.
    Splinter TAW: Chemotherapy in advanced non-small cell lung cancer. Eur J Cancer 1990 (26): 1093–1099PubMedCrossRefGoogle Scholar
  3. 3.
    Sandler AB, Buzaid AC: Lung cancer: a review of current therapeutic modalities. Lung 1992 (170):249–265PubMedCrossRefGoogle Scholar
  4. 4.
    Ihde DC: Chemotherapy of lung cancer. N Engl J Med 1992 (327): 1434–1441PubMedCrossRefGoogle Scholar
  5. 5.
    Rapp E, Pater JL, Willan A, Cormier Y, Murray N, Evans WK, Hodson Dl, Clark DA, Feld R, Arnold AM, Ayoub Jl, Wilson KS, Latreille J, Wierzbicki RF, Hill DP: Chemotherapy can prolong survival in patients with advanced non-small cell lung cancer - report of a Canadian multicenter randomized trial. J Clin Oncol 1988 (6):633–641Google Scholar
  6. 6.
    Souquet PJ, Chauvin F, Boissel JP, Cellerino R, Cormier Y, Ganz PA, Kaasa S, Pater JL, Quoix E, Rapp E, Tumarello D, Williams J, Woods BL, Bernard JP: Polychemotherapy in advanced non-small cell lung cancer: a meta-analysis. Lancet 1993 (342): 19–21PubMedCrossRefGoogle Scholar
  7. 7.
    Grilli R, Oxman AD, Julian JA: Chemotherapy for advanced non-small cell lung cancer: how much benefit is enough? J Clin Oncol 1993 (11):1866–1872PubMedGoogle Scholar
  8. 8.
    Smith IE: Palliative chemotherapy for advanced non-small cell lung cancer. Br Med J 1994 (308): 429–430CrossRefGoogle Scholar
  9. 9.
    Carmichael J, Possinger K, Philip P, Beykirch M, Kerr H, Walling J, Harris AL: Difluorodeoxycytidine (gemcitabine): a phase II study in patients with advanced breast cancer. ASCO Proceedings 1993 (12):64 #57Google Scholar
  10. 10.
    Lund B, Hansen OP, Theilade K, Hansen M, Neijt JL: Phase II study of gemcitabine in previously platinum treated ovarian cancer patients. An update. ASCO Proceedings 1993 (12):262 #834Google Scholar
  11. 11.
    Eisenhauer E, Cormier Y, Gregg R, Stewart D, Muldal A: Gemcitabine is active in patients with previously untreated extensive small-cell lung cancer. A phase II study of the National Cancer Institute of Canada Clinical Trials Group. ASCO Proceedings 1992 (11):#1043Google Scholar
  12. 12.
    Anderson H, Final report accepted by J Clin OncolGoogle Scholar
  13. 13.
    Abratt R, Final reported accepted by J Clin OncolGoogle Scholar
  14. 14.
    Gatzemeier V, abstract: accepted for publication, 7th World Lung Conference, Colorado Springs, 1994Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1994

Authors and Affiliations

  • Thierry Le Chevalier
    • 1
  1. 1.Comité de Pathologie ThoraciqueInstitut Gustave RoussyVillejuif CedexFrance

Personalised recommendations